The Possible Effects of Roflumilast on Obesity Related Disorders

Inclusion criteria

• Prediabetic patients (fasting blood glucose between 100 mg/dl and 125 mg/dl or HbA1C within the range 5.7% and 6.4%).
• Obese subjects (BMI ≥30 kg/m2 and <40 kg/m2).

Exclusion criteria

• Patients with morbid obesity (BMI > 40 kg/m2).
• Patients already on weight lowering agents or weight loss program.
• History or current diagnosis of major depressive disorder or other psychiatric disorders that in the opinion of the investigator would make participation unsafe for the participant.
• Moderate to severe liver disease (Child-Pugh B or C), renal disease, thyroid disease, cardiovascular disease, peripheral vascular disease or coagulopathy.
• Women will be excluded from our study if they are pregnant, breastfeeding, currently on contraceptive pills or if they plan to become pregnant prior to the end of the study.
• Patients on medications that can interfere with glucose or lipid metabolism (e.g. hypoglycemic agents, corticosteroids, anti-hyperlipidemics, non-selective β-blockers thiazides, etc.) and subjects with organic causes of obesity.
• Diabetic patients and patients with any inflammatory disease.
• Smokers.
• Patients on cytochrome P450 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin, etc.)